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Edited by Horst FeldmannAbstract Proteases were, for a long time, mainly considered as
protein degrading enzymes. However, in the last decade this view
has changed dramatically, and the focus is now on proteases as
signalling molecules. One of the best examples is apoptosis,
the major mechanism used by eukaryotes to remove superﬂuous,
damaged and potentially dangerous cells, in which a number of
proteases have been found to play a central role. Of these the
caspases have been considered to be the major players. However,
more recently, other proteases have been increasingly suggested
as being important in apoptosis, in particular the cysteine
cathepsins. In this review the roles of caspases and cysteine
cathepsins in apoptosis signalling are compared and discussed.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Maintenance of the population of cells is central to the
development and homeostasis of all eukaryotic organisms. Re-
moval of superﬂuous cells, including those that are damaged
and potentially dangerous, can be accomplished in several
ways, the best known and characterized being apoptosis. When
apoptosis is deregulated, cells either fail to die, as in a number
of pathologies such as cancer and other hyperproliferative dis-
eases, or die excessively, as in a number of neurodegenerative
disorders and AIDS [1–3].
Proteases are among major molecular machines in the
organism. They also play a central role in the execution phase
of apoptosis, and the caspases (cysteine aspartate-speciﬁc pro-
teases), a family of cysteine proteases, are of major importance
[4,5]. Later, a number of other proteases, including granzymes,
cathepsins and calpains, were also found to be involved in cell
death [6]. In order to begin to understand how such proteasesAbbreviations: BH3, Bcl-2 homology region 3; Bid, BH3-interacting
domain death agonist; CARD, caspase recruitment domain; DED,
death eﬀector domain; DISC, death-inducing signalling complex; IAP,
inhibitor of apoptosis protein; TNF, tumor necrosis factor
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doi:10.1016/j.febslet.2007.05.038can dismantle a cell or signal to its dismantling, one has to
understand what protease signalling is in this context. The ba-
sic function of a protease is to cleave proteins and thereby irre-
versibly modulate the properties of the substrate. As a
consequence of a cleavage or a series of cleavages, proteins
either gain a function, – activation by limited proteolysis –
or lose a function, ultimately being turned over. Proteases
are generally synthesized as inactive precursors that require
activation, most often by limited proteolysis, thereby being
protease substrates themselves. Such protease signalling, as a
way of signal transduction, is therefore irreversible, thereby
diﬀering from other signalling mechanisms [7]. Due to this irre-
versibility, protease signalling is an eﬀective way of killing a
cell, as the cell death, once the program has started, cannot
be reversed or prevented. This review will be devoted to casp-
ases and cysteine cathepsins and to discussion of their role in
apoptotic cell death.2. Caspases
There are 11 caspases in humans and they are known to be
extremely speciﬁc, cleaving their substrates exclusively after
Asp residues [8], although they diﬀer in their P2–P4 speciﬁcity
[9]. Some of them are implicated in apoptosis (caspases 2, 3, 6,
7, 8, 9, and 10), while others are involved in activation of pro-
inﬂammatory cytokines (caspases 1, 4, 5) or in keratinocyte
diﬀerentiation (caspase 14) [10]. Proapoptotic caspases can
be divided into the initiator caspases (2, 8, 9, and 10) and
the executioner caspases (3, 6, and 7), based on their role in
apoptosis [8]. All the initiator caspases have long prodomains,
such as DED (death eﬀector domain) and CARD (caspase
recruitment domain), and occur in the cytosol as inactive
monomers [11]. On the other hand the executioner caspases ex-
ist as dimers in the zymogen form [11]. Activation of the initi-
ator caspases is probably the critical point in the whole
pathway. There are two major pathways known to lead to cas-
pase activation, the extrinsic and intrinsic pathways [12]
(Fig. 1). In the ﬁrst, binding of death ligands from the TNF
(tumor necrosis factor) family leads to oligomerization of the
death receptors of the TNF receptor family. These in turn bind
the adapter proteins such as FADD (Fas Associated protein
with Death Domain) thereby forming the DISC (death-induc-
ing signalling complex), which serves as an activation platform
for caspases 8 and 10. The intrinsic or mitochondrial pathway
is triggered by cell stress, which leads to activation of proapop-
totic BH3 (Bcl-2 homology region 3)-only members of the Bcl-
























Fig. 1. Protease signalling in apoptosis. Following an apoptotic stimuli as a result of extracellular signal or due to intracellular stress, a proteolytic
cascade involving caspases is triggered. Zymogens of the initiator caspases-8, -9 and/or -10 are recruited to the activation platforms, Disc in case of
the extrinsic pathway or apoptosome in case of the intrinsic pathway, where they are activated via dimerisation. Activated initiator caspases in the
next step activate the executioner caspases-3, -6 and/or -7, leading to substrate cleavage and apoptosis. Activation of the intrinsic pathway involves
mitochondria, which participate in the process by releasing cytochrome c and other apoptogenic proteins such as endonuclease G, Smac/Diablo and
Omi/HtrA2, via a mechanism involving Bak and/or Bax. In the lysosomal pathway, cathepsins are released from lysosomes to cytosol following
lysosomal membrane permeabilization. Once in the cytosol, they activate proapototic molecules such as Bid or inactivate antiapoptotic Bcl-2
proteins. Other cathepsin substrates in apoptosis are currently unknown. The major control points in the cytosol are Bcl-2 proteins, Smac/Diablo,
Omi/HtrA2 and IAPs, which regulate caspase activity and activation, and steﬁns and/or serpins, which regulate cysteine cathepsin activity. Further
details are provided in the main text.
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(BH3-interacting domain death agonist) and Bad (Bcl-xL/
Bcl-2 associated death promoter). This is followed by seques-
tration of antiapoptotic Bcl-2 proteins including Bcl-2 (B-cell
lymphoma-2), Mcl-1 (myeloid cell leukemia-1), Bcl-XL (Bcl-
xLong), thereby enabling Bax (Bcl-2-associated · protein) and/
or Bak (Bcl-2 homologous antagonist/killer) oligomerization
and activation. Although there may be alternative mechanisms
for the role of BH3-only and Bcl-2 proteins in Bax and Bak
oligomerization, the outcome is the same and activated Bax
and Bak make pores in the mitochondrial membrane, leading
to the release of proapoptogenic factors such as cytochrome c,
Smac/Diablo [second mitochondria-derived activator of cas-
pase/direct IAP (inhibitor of apoptosis protein)-associated
binding protein with low PI], AIF (apoptosis-inducing factor),
the serine protease Omi/HtrA2 (High temperature requirement
protein A2) and endonuclease G [3]. Cytochrome c then binds
to Apaf-1, resulting in a conformational change in the latter,
leading to oligomerization of Apaf-1 and formation of the
apoptosome. The apoptosome then, similarly to the DISC
complex, serves as an activation platform for caspase-9. Initi-
ator caspases are recruited via their recruitment domains, such
as DED (caspases 8 and 10) or CARD (caspase-9), to the acti-
vation platforms, where they are activated in an allosteric
manner, i.e. via a conformational change induced by dimeriza-
tion of two inactive monomers [11]. Activated initiator casp-
ases then directly activate executioner caspases by proteolytic
activation. Alternatively, in type II cells (cells can be catego-
rized as type II cells if anti-Fas-mediated apoptosis can be
blocked by overexpression of Bcl-2), activated caspase 8 may
cleave and activate the proapoptotic BH3-only protein Bid,
which triggers the intrinsic pathway through Bak and Bax [13].
In addition, a third pathway exists, although it is limited to
NK and T-cells. It involves granzyme B, a serine protease withAsp speciﬁcity found in the granules of the cytotoxic T-cells.
Granzyme B can activate caspases when delivered to the target
cell, assisted by perforin either directly through cleavage acti-
vation of caspase-3 or indirectly through Bid cleavage and
engagement of the intrinsic pathway [14].
Following activation, the executioner caspases are the real
hunters looking for prey in the cytosol. Through a limited
number of cleavages they process a subset of cellular proteins,
of which 300 have been identiﬁed in various models of apop-
totic cell death [15]. The great majority of caspase substrates
lose their function as a consequence of these cleavages, while
a few gain a function through proteolytic activation. Caspases
cleave a number of proteins including those involved in DNA
synthesis, cleavage and repair such as PARP [poly(ADP-ri-
bose) polymerase] and ICAD (Inhibitor of Caspase-Activated
Dnase) proteins involved in translation, cell cycle regulators,
cytoskeletal proteins, adhesion proteins, protein kinases and
phosphatases, proteins involved in G protein signalling, splice-
osome proteins and many others [4,5,10,15,16]. As a conse-
quence, a number of vital functions of the cell are disabled,
and the cell dies (see Table 1).
However, not all the cleavages are the consequence of cas-
pase action [16]. Sometimes caspases just perform the ﬁrst
cleavage and let other proteases ﬁnish the job. A good example
is the activation of Acinus, a protein involved in chromatin
condensation, which requires a second cleavage by a non-cas-
pase protease to induce activity [17]. Moreover, the number of
caspase substrates in a well-deﬁned pathway in a single cell is
probably relatively small, as only about 90 diﬀerent caspase
substrates were identiﬁed in Fas apoptosis using a proteomics
approach [16]. This further suggests that little is needed to kill
a cell, the dirty job of clearing the corpses being done by
phagocytes, probably involving lysosomal proteases for termi-
nal degradation of the engulfed material.
Table 1
Comparison between caspases and cysteine cathepsinsa
Feature Caspases Cathepsins
Clan type CD14 CA1
Name Caspase family Papain family
Catalytic type Cysteine protease Cysteine protease
Catalytic mechanism Histidine (H236) and cysteine (C284)
form a catalytic dyad. These catalytic
residues are found in motifs such as
histidine–glycine and alanine–cysteine
conserved throughout clan CD
Cysteine (C158) and histidine (H292) catalytic dyad is
distinct from clan CD and form a thiolate-immidazolium
ion pair in the active form. Asparagine/aspartate (N/Q308)
assists to orientate the imidazolium ring of the catalytic
histidine residue
Enzyme activity Endopeptidases only. Substrate speciﬁcity
exclusively for an aspartate residue in the
P1 position. Extended caspase substrate
speciﬁcity is deﬁned by the amino acids
residues primarily present in the P2–P4
positions
The family includes endo- and exo-peptidases. The dominant
subsite speciﬁcity resides in the P2 position with preference
for uncharged or bulky hydrophobic side chains, with the
exception of cathepsin B that accepts basic amino acids residues.
Extended speciﬁcity is a result of concerted contribution from
several sites
pH optimum Neutral pH Acidic to neutral pH
pH stability Narrow (around neutral) Acidic pH (good below pH 6.0)
Protein substrate processing Single cleavage or discrete pattern with
few cleavages
Stepwise degradation, although processing via limited proteolysis
possible (autocatalytic activation, Bid activation)
Activation mechanism Caspases exist as inactive monomers
(initiators) or dimers (executioners),
which are activated by dimerization
without proteolysis or by internal
limited proteolysis
Synthesised as inactive proenzymes with N-terminal propeptides
cleaved autocatalytically or by other proteases to generate a single
or double chain active enzyme (except for cathepsin C, which is a
tetramer)
Protein fold Belongs to the class of a and b
proteins (a/b)
Belongs to the class of a and b proteins (a + b)
Caspase-like fold (SCOP: 52128) consists
of three layers a/b/a with a core of mixed
b-sheet of six strands (in the order 213456)
and strand 6 is antiparallel to the rest
Cysteine proteinases fold (SCOP: 54000) consists of one a-helix
and four strands of antiparallel b-sheet thus containing the catalytic
triad Cys-His-Asn
Biological role Proteases involved in apoptosis and
inﬂammation
Proteolytic machinery in the lysosomal system of eukaryotic cells
and the digestive vacuoles of protozoa. Also other functions
Distribution Animals All kingdoms
Localization Cytosol Lysosomes
Cell death phenotype Apoptosis Necrosis, apoptosis, autophagy
Clinical relevance Enzyme targets for inﬂammation and
apoptosis-related disorders
Targets for osteoporosis and inﬂammation; possible targets for
cancer, diabetes and obesity
aSome data can be found in MEROPS, an extensive of protease database at http://merops.sanger.ac.uk/.
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Inappropriate activation of caspases leads to a fatal outcome,
therefore their activity needs to be tightly regulated. This regu-
lation starts at the transcription level, at least in the neuronal
system, where caspase-3 was found to be almost completely shut
down in the adult [18,19]. However, following an insult, tran-
scription can be reactivated, leading to normal neuronal cell
death, as shown in a model of ischemic injury [18]. The major
regulation checkpoints are at the level of activation of initiator
caspases. The extrinsic pathway is mostly regulated prior to
death receptor activation outside the cell, although FLIP
(FLICE-like inhibitory protein), the inactive caspase-8 homo-
logue, may regulate activation of caspase-8 as positive or nega-
tive regulators, depending on their concentration [20]. The
intrinsic pathway has a much more complex regulation, having
all the components simultaneously present within the cell.Mito-
chondria play the central regulatory role, with control points
being both upstream and downstream of them (Fig. 1). The ma-
jor upstream regulators are the Bcl-2 family proteins which reg-
ulate the release of proapoptogenic factors (cytochrome c,
Smac/Diablo, Omi/HtrA2, etc.) from mitochondria. The proa-
poptotic Bax/Bak proteins are directly responsible for making
pores in mitochondria, but are blocked by the antiapoptotic
Bcl-2 homologues (Bcl-2, Bcl-XL, Mcl-1, A1, Bcl-w). On the
other hand, proapoptotic BH3-only proteins (Bid, Bad, Bim,
Noxa, Puma, Hrk, Bmf) serve either to sequester the antiapo-ptotic proteins or to bypass them and directly activate Bak/
Bak proteins [3,21]. Downstream of mitochondria, accidental
caspase activation is neutralized by XIAP (X-linked IAP), the
direct inhibitor of caspases-3, -7 and -9 [22,23], which provides
a threshold that has to be overcome in order to trigger apoptosis
[24]. On the other hand, the function of Smac/Diablo and Omi/
HtrA2, which are released from mitochondria together with
cytochrome c, opposes the function of XIAP [3]. Both Smac
and Omi contain IAP-binding motifs (IBMs) through which
they interact with IAPs, thereby sequestering them and ensuring
that cells really undergo apoptosis [23]. In addition, the cascade
organization of caspases provides a further level of regulation
and the possibility of major ampliﬁcation of the signal.3. Cathepsins
Cathepsins are a group of proteases found predominantly in
lysosomes. The best characterized are the cysteine cathepsins, a
family of papain-like enzymes consisting of 11 known mem-
bers in human (B, C, F, H, K, L, O, S, V, X, W) [6,25,26].
An abundant lysosomal cathepsin is the aspartic protease
cathepsin D [27]. In contrast, cathepsin G is a serine protease
found in azurophilic granules in neutrophils, which have the
same role as the lytic granules in cytotoxic T lymphocytes that
contain the granzymes [6].
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cycle proteins within lysosomes. Another important function
is to process antigens to antigenic peptides for presentation
to the MHC class II molecules, thereby being crucial to the im-
mune response [25,26]. They are well suited for these roles by
their relatively low speciﬁcity and by functioning in a reducing
environment at acid pH, which may help to, at least partially,
unfold their substrates. The majority of the cathepsins are
endopeptidases (B, L, S, K, F, D, V), but some are exopeptid-
ases (B, X, C, H); collectively, they enable eﬃcient protein deg-
radation. Moreover, their localization in the endosomal/
lysosomal compartment, where they are separated from the
rest of the cellular proteins to prevent their harmful action,
provides them with an excellent working environment. There
is a lot of redundancy in the system, as none of the single
cathepsin knock-outs was found to cause any defect in intra-
cellular turnover [28]. However, animals with ablated genes
for cathepsin D or simultaneous ablation of genes for cathep-
sins B and L were found to die due to massive neuronal cell
death, presumably as a consequence of defects in the terminal
steps of autophagy [29]. This is consistent with the critical role
of cathepsins in the terminal degradation of recycled proteins
within autolysosomes, following the fusion of autophagosomes
and lysosomes [30].
Cathepsins thus have enormous destructive potential and it
is not surprising that massive lysosomal rupture was found
to lead to necrotic cell death [31]. However, moderate lyso-
somal damage was shown to lead to apoptotic cell death,
sometimes without the apparent activation of caspases,
although the mechanisms are less well deﬁned. The ﬁrst re-
ports, suggesting initially cathepsin D [32] and later cysteine
cathepsins [33,34] to be implicated in this type of cell death
came some ten years ago. Apoptotic cell death involving
cathepsins requires their release from the lysosomes into the
cytosol. This could be achieved by a number of stimuli, involv-
ing detergents, oxidative stress and anticancer drugs, which
were found to be capable of relatively selectively disrupting
lysosomes [30,35,36]. Once in the cytosol, cathepsins may
cleave a number of substrates, thus signalling cell death. This
immediately raises the following questions: (i) what are the cel-
lular substrates of cathepsins and (ii) can cathepsins kill the
cell(s) by themselves? Although cathepsin D was often sug-
gested to be involved in caspase-dependent and -independent
cell death [32,37], the role of active cathepsin D is intriguing
as, in a number of studies, the activity of cathepsin D was rou-
tinely checked at acid pH (<4), using haemoglobin as a sub-
strate [37]. Cathepsin D exhibits very little or no activity on
protein or peptide substrates at pH 5 and above, due to depro-
tonation of both the active site Asp residues [38]. The enzyme
can thus remain latent at neutral pH for a longer period of
time, but immediately exhibits proteolytic activity at lower
pH, a feature successfully used in all puriﬁcation procedures
[27]. Consistent with this idea are the ﬁndings that ﬁbroblasts
expressing catalytically inactive cathepsin D were not pro-
tected against stress-induced apoptosis [39].
In an in vitro experiment carried out at acid pH and under
reductive conditions, thus mimicking the lysosomal environ-
ment, cysteine cathepsins cleaved and possibly degraded the
vast majority of proteins. However, when released into the
cytosol, cathepsins face unfavourable conditions as the pH is
close to neutral. Although cathepsins are still active at neutral
pH, their life-time under these conditions is limited due tounfolding-induced inactivation, which varies from enzyme to
enzyme [6,40]. Acidiﬁcation of the cytosol during apoptosis
and ligand binding may, however, prolong their life-time to
a certain extent [40,41]. Moreover, these conditions are proba-
bly also more favourable for their potential substrates and ren-
der them less susceptible to proteolysis, as low pH and
reducing conditions may induce partial unfolding or, at least,
some loosening of the structure of proteins, thereby making
them more suitable as cathepsin substrates. Consistent with
these ideas, only a very few cellular substrates of cathepsins
have been identiﬁed. Proapoptotic caspases, which could be
very suitable candidates, are not among them, although some
other proteases were found to activate caspases under special
conditions [10,34]. Initially, cathepsins were suggested to be
able to process proinﬂammatory caspases [42]. However, it is
now known that activation of proinﬂammatory caspases also
requires activation platforms such as the inﬂammasome [43].
Instead, this processing was most probably associated with
slow time-dependent degradation of the caspases, as no cas-
pase activity could be detected following caspase-1 and -11
processing (Rozman-Pungercar et al., unpublished). Bid re-
mains the best characterized of the cathepsin substrates, ini-
tially discovered as a cathepsin substrate in a cell free system
[34]. Later, Bid was conﬁrmed as a cathepsin substrate in a
variety of cell models [44,45]. Moreover, in vitro studies dem-
onstrated that a number of cysteine cathepsins, including
cathepsins B, L, S and K, cleave Bid, predominantly at
Arg65 [44], consistent with previous data on lysosomal extracts
[34], suggesting that there is some redundancy in the system.
However, Bid is deﬁnitely not the only cellular substrate of
cathepsins, as ablating it, together with steﬁn B, the major
intracellular inhibitor of cysteine cathepsins, did not rescue
neuronal apoptosis in steﬁn B-deﬁcient animals [46]. In keep-
ing with this, we have recently identiﬁed the antiapoptotic
Bcl-2 family members Bcl-2, Bcl-XL and Mcl-1 as cathepsin
substrates. However, in contrast to the activation cleavage of
Bid, they were found to be degraded during LeuLeuOMe-in-
duced apoptosis (Droga-Mazovec et al., in preparation). In
addition, in cancer, cathepsins were also found to degrade E-
cadherin, a cell adhesion molecule [47], which is also cleaved
by caspases [48]. Despite numerous studies indicating the
importance of cathepsins for apoptosis progression in a num-
ber of diﬀerent apoptotic models, no further cathepsin sub-
strates have been identiﬁed. This includes also the death
receptor pathway, where cathepsins, especially cathepsin B,
were suggested to be of major importance [33,49], which ar-
gues against the predominant role of cathepsins as execution-
ers of cell death in apoptotic cell death. Instead, most studies
suggest that cathepsin-mediated cell death proceeds through
destabilization of mitochondria [33,34,36,44,45,50–53], which
is consistent with the idea that cathepsins trigger cell death
via Bid activation, accompanied by the cleavage of antiapopto-
tic Bcl-2 family members (Fig. 1). This is further supported by
the ﬁndings that cell death was largely prevented when casp-
ases were blocked in several models of lysosome-induced cell
death [44,45]. However, the possibility that the cathepsins
may indeed be the major executioners in a certain, speciﬁc sit-
uation cannot be excluded, especially since the standard cas-
pase inhibitors, including z-VAD-fmk, were found to inhibit
the cathepsins at higher concentrations comparable to those
often used in apoptosis studies [54]. This would, however, re-
quire a more systematic approach, similar to that used for
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novel cathepsin substrates. In addition, the cathepsins could
probably assist caspases at the very late stage of apoptosis if
released from lysosomes, although in that case they could have
no major role in apoptosis signalling.3.1. Cathepsin activity regulation
One of the important questions is how the activity of cathep-
sins can be prevented or regulated if they leak from the lyso-
some. Cathepsins are fully active within lysosomes and are
translocated to the cytosol as active enzymes. Although their
activity is partly regulated by the unfavourable neutral pH,
their endogenous inhibitors, steﬁns, cystatins, serpins and thy-
ropins, constitute the major defence mechanism [24,55]. Under
these conditions, the pH inactivation of proteases is consider-
ably slower than their inhibition, which is practically instanta-
neous [40]. The essential role of inhibitors was conﬁrmed, in an
in vivo model of cerebellar apoptosis, to be a consequence of
ablation of steﬁn B, the major intracellular inhibitor of cathep-
sins [46,56]. The inhibitors thus provide a certain threshold to
prevent inappropriate activity of cathepsins accidentally found
in the cytosol [24]. Nevertheless, the regulation of cathepsin
activity outside lysosomes is less precise than is the case with
caspases, which may explain why cathepsins appear to be more
prone to catastrophic events, such as necrosis.4. A comparison between caspases and cathepsins in cell death
When looking at caspases and cysteine cathepsins, it is
immediately clear that there are a number of diﬀerences be-
tween the two protease families: (i) although they are both cys-
teine proteases, the caspases have an exclusive speciﬁcity for
Asp residues in the P1 position, whereas the cathepsins have
a broad speciﬁcity, with some preference for hydrophobic or
basic residues in the P2 position; (ii) caspases reside as inactive
zymogens in the cytosol and await a death signal leading to
their activation, whereas cysteine cathepsins are already active
within the lysosomes and need to be translocated to the cytosol
to exert their proapoptotic function; (iii) although both casp-
ases and cathepsins almost always inactivate their substrates,
caspases cleave them at a single site or at a few sites only,
whereas cathepsins process them by stepwise degradation –
activation of Bid being an exception to the rule; (iv) regulation
of caspases is much more tightly controlled than the regulation
of cathepsins; (v) caspases are designed to work in the cytosolic
milieu, whereas cathepsins are struggling in the cytosol due to
unfavourable pH. Despite these diﬀerences, both protease
types can kill the cell under diﬀerent circumstances. Following
activation, caspases dismantle a cell through a series of precise
cleavages, inactivating and activating a number of cellular sub-
strates. However, during moderate lysosomal damage, cathep-
sins most probably have a much more benign role than
caspases, only cleaving a small subset of cellular proteins, lead-
ing to mitochondrial damage and subsequent activation of the
latter. It can therefore be suggested that apoptotic cell death
induced by cysteine cathepsins is predominantly caspase-
dependent. The real killers thus appear to be the caspases
and not the cathepsins, although the latter may be very helpful
in situations where caspase activation is dampened due to
overexpression of various antiapoptotic proteins, such as incancer [2,57,58]. Indeed, quite a few anticancer drugs have
been already shown to work through lysosomal disruption,
although their mechanisms have not been studied in detail.
On the other hand, cathepsins can probably kill cells during
necrosis following massive lysosomal rupture without major
help from other proteases. However, necrosis is very harmful
for the organism and would only occur under more harsh con-
ditions where other control mechanisms fail.5. Conclusion
In conclusion, caspases are likely to be the major players in
apoptosis, while the function of the cathepsins appears to be
marginal and is probably limited to assistance in caspase acti-
vation. This is consistent with the major functions of the two
protease families: execution of apoptosis for caspases and
intracellular protein turnover within lysosomes for cathepsins.
What appears to be a full-time job for a caspase is only a part-
time job for a cathepsin in apoptosis. Ironically, caspases live
mostly to achieve a single goal: to become mass murderers
and to get their few minutes of glory before the curtain falls
and the corpses are cleared away by the professionals, leaving
no traces of the crime or the criminals. The end – no more her-
oes anymore!
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